print-logo
Logo
  • Healthcare Consultants
  • Healthcare Managers
  • Who we are Arrow Down
    • About us
    • Our purpose & values
    • Our team
    • News & events
  • What we do Arrow Down
    • Overview
    • Market Access
    • Medical Affairs
    • Government Affairs
    • Commercial
    • Patient Advocacy
    • Lifecycle Management
  • Insights Arrow Down
    • Publications
    • Project cases
    • Early Asset Strategy
    • Value Pull-Through
    • Environment Transformation
  • Careers Arrow Down
    • Why join us
    • Open positions
    • Career paths
    • FAQ
  • Contact
  • Search Icon
  • Healthcare Consultants
  • Healthcare Managers
  • Search Icon
  • Search
Back to Project cases
  • linkedin_icon
  • twitter_icon
  • mail_icon
  • print_icon

Early asset assessment informing indication development

Early asset assessment informing indication development_560x400.jpg

Goal

The client had an ongoing phase 2b read-out in a rare diseases dermatology indication for a biologic that will be launched in another immunology indication. In anticipation of the 52 weeks data read-out the client wanted to understand the unmet needs, prioritize the value drivers, assess the future competitors and derive the strategic implications for the future clinical development, by working closely with the global and US cross-functional teams.

Approach

Unmet needs

Map the current patient journey and prioritize the primary unmet needs

Value drivers

Prioritize value drivers based on impact for healthcare stakeholders

Future success

Assess future competitors and derive strategic implications

  • Early asset assessment informing indication development
  • Aligned the cross-functional global and US team on the unmet needs across all healthcare stakeholders
  • Prioritized the value drivers from a global perspective given currently available treatments
  • Assessed future competitors based on the still limited clinical evidence available in the public domain
  • Agreed on “market winning” & nice-to-have value drivers for further indication development

Contact our experts

Paul Gardiner

Paul Gardiner

Director

mail_icon linkedin_icon
Ewa Kania

Ewa Kania

Consultant

mail_icon linkedin_icon

Learn more about our focus topic

Early Asset Strategy
Share this page
  • linkedin_icon
  • twitter_icon
  • mail_icon
  • print_icon

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.

OK
arrow_up

How can we help?

Contact us

Our offices

Careers

Footer Logo
  • Who we are
  • What we do
  • Insights
  • Careers
  • Contact
  • Terms of use
  • Privacy policy
  • Imprint

2023 Executive Insight. All rights reserved.